In the last trading session, 2.54 million Unicycive Therapeutics Inc (NASDAQ:UNCY) shares changed hands as the company’s beta touched 2.35. With the company’s per share price at $0.38 changed hands at -$0.03 or -7.45% during last session, the market valuation stood at $35.62M. UNCY’s last price was a discount, traded about -378.95% off its 52-week high of $1.82. The share price had its 52-week low at $0.20, which suggests the last value was 47.37% up since then. When we look at Unicycive Therapeutics Inc’s average trading volume, we note the 10-day average is 2.03 million shares, with the 3-month average coming to 2.42 million.
Analysts gave the Unicycive Therapeutics Inc (UNCY) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended UNCY as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Unicycive Therapeutics Inc (NASDAQ:UNCY) trade information
Instantly UNCY was in red as seen at the end of in last trading. With action -13.69%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -56.49%, with the 5-day performance at -13.69% in the red. However, in the 30-day time frame, Unicycive Therapeutics Inc (NASDAQ:UNCY) is 11.75% up. Looking at the short shares, we see there were 0.38 million shares sold at short interest cover period of 0.11 days.
Unicycive Therapeutics Inc (UNCY) estimates and forecasts
Data shows that the Unicycive Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -72.64% over the past 6 months, a 0.00% in annual growth rate that is considerably lower than the industry average of 20.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -77.09%. The 2024 estimates are for Unicycive Therapeutics Inc earnings to increase by 42.97%.
UNCY Dividends
Unicycive Therapeutics Inc is expected to release its next quarterly earnings report in November.
Unicycive Therapeutics Inc (NASDAQ:UNCY)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 6.73% of Unicycive Therapeutics Inc shares while 30.24% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 32.42%. There are 30.24% institutions holding the Unicycive Therapeutics Inc stock share, with VIVO CAPITAL, LLC the top institutional holder. As of 2024-06-30, the company held 9.9395% of the shares, roughly 3.47 million UNCY shares worth $1.74 million.
LOGOS GLOBAL MANAGEMENT LP holds the second largest percentage of outstanding shares, with 9.9389% or 3.47 million shares worth $1.74 million as of 2024-06-30.
